Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.540
-0.640-1.99%
Volume:9.96M
Turnover:314.16M
Market Cap:191.26B
PE:28.92
High:32.860
Open:32.380
Low:31.180
Close:32.180
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.25
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:1.57%
EPS(LYR):1.091
ROE:19.40%
ROA:9.08%
PB:4.32
PE(LYR):28.92
PS:10.26

Loading ...

Oral Cyclic Peptides Enter Validation Phase, Opening a Multi-Billion Dollar Therapeutic Arena

Stock News
·
Jul 22

Hansoh Pharmaceutical Group Stock Slips 1.5% in Hong Kong

Dow Jones
·
Jul 21

Movement Alert|Hansoh Pharmaceutical Declines 3.33% in Regular Trading, Trading at HK$31.98

Market Focus
·
Jul 21

Hansoh Pharmaceutical Group Stock Rises 4.0% in Hong Kong

Dow Jones
·
Jul 20

Movement Alert|Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Pharmaceutical Sector Recovery Coupled with Multiple Pipeline Catalysts

Market Focus
·
Jul 20

Hansoh Pharmaceutical Group Stock Falls 4.1% in Hong Kong

Dow Jones
·
Jul 17

Movement Alert|Hansoh Pharmaceutical Falls 3.08% in Regular Trading, Broad Pharmaceutical Sector Weakness Drags Shares Lower

Market Focus
·
Jul 17

Movement Alert|Hansoh Pharmaceutical Rises 3.17% in Regular Trading, Multiple Catalysts Including Avere-NextCure Merger and HS-20093 Phase III Success Drive Momentum

Market Focus
·
Jul 16

Hansoh Pharma Earns MSCI ESG AAA Rating

Reuters
·
Jul 15

HANSOH PHARMA Shares Surge on Global Licensing Deal and Merger Announcement

Stock News
·
Jul 15

Movement Alert|Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure

Market Focus
·
Jul 15

Hansoh Pharmaceutical Discloses Transactions with Avere Therapeutics

Reuters
·
Jul 14

Hansoh Pharma Licenses Oral IL-23 Drug Hs-20118 to Avere in Deal Worth up to USD 2.3 Billion

Reuters
·
Jul 14

Hansoh-backed Avere Agrees to Merge with Nextcure in All-stock Deal

Reuters
·
Jul 14

Hansoh Pharmaceutical - Avere Therapeutics to Merge into Nextcure Under Merger Agreement Signed July 14, 2026

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical - Combined Entity to Operate as Avere Therapeutics, and Trade as Avrx

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical - Hanshoh Pharma to Hold over 30% but Under 40% of Combined Entity Post-merger

THOMSON REUTERS
·
Jul 14

Hansoh Pharmaceutical Group Stock Rises 1.8% in Hong Kong

Dow Jones
·
Jul 13

HANSOH PHARMA Shares Surge on Positive Phase III Trial Results for Lung Cancer Drug

Stock News
·
Jul 13

Movement Alert|Hansoh Pharma Rises 3.51% in Regular Trading, Core ADC Drug HS-20093 Achieves OS Primary Endpoint in Phase III SCLC Trial

Market Focus
·
Jul 13